1738-82-5

Basic information

• Product Name: GLY-GLY BENZYL ESTER P-TOLUENESULFONATE SALT
• Synonyms: GLYCYLGLYCINE BENZYL ESTER P-TOLUENESULFONATE;GLYCYLGLYCINE BENZYL ESTER P-TOLUENESULFONATE SALT;GLYCYL-GLYCINE BENZYL ESTER-P-TOSYLATE;GLY-GLY BENZYL ESTER P-TOLUENESULFONATE SALT;H-GLY-GLY-OBZL P-TOSYLATE;H-GLY-GLY-OBZL TOS;H-GLY-GLY-OBZL TOSOH;GLY-GLY BENZYL ESTER P-TOLUENESULFONATE
• CAS NO: 1738-82-5
• Molecular Formula: C₇H₇O₃S*C₁₁H₁₅N₂O₃
• Molecular Weight: 394.44
• Product Categories: Dipeptides;Dipeptides and Tripeptides;Peptides
• Mol File: 1738-82-5.mol

Chemical Properties

• Melting Point: 157-159℃
• Boiling Point: 408 °C at 760 mmHg
• Flash Point: 200.5 °C
• Appearance: White powder
• Vapor Pressure: 7.26E-07mmHg at 25°C
• Storage Temp.: 2-8°C
• CAS DataBase Reference: GLY-GLY BENZYL ESTER P-TOLUENESULFONATE SALT(CAS DataBase Reference)
• NIST Chemistry Reference: GLY-GLY BENZYL ESTER P-TOLUENESULFONATE SALT(1738-82-5)
• EPA Substance Registry System: GLY-GLY BENZYL ESTER P-TOLUENESULFONATE SALT(1738-82-5)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 1738-82-5(Hazardous Substances Data)

Usage

Uses

Used in Biochemistry and Pharmaceutical Research:
Gly-Gly benzyl ester p-toluenesulfonate salt is used as a protective group in peptide synthesis for the selective modification of specific amino acids within a peptide chain. This selective modification is crucial for the study of protein structure, function, and interactions.
Used in Synthetic Peptide Production:
Gly-Gly benzyl ester p-toluenesulfonate salt is used as a key component in the production of synthetic peptides for a variety of research and medical applications. Its protective group function allows for the synthesis of complex peptide sequences with specific modifications, which can be used for therapeutic purposes or as research tools.
Used in Drug Development:
The unique properties of Gly-Gly benzyl ester p-toluenesulfonate salt make it a valuable tool in drug development. Its ability to selectively modify amino acids within peptide chains can be leveraged to design and synthesize novel peptide-based drugs with specific therapeutic targets and improved pharmacological properties.

InChI:InChI=1/C11H14N2O3.C7H8O3S/c12-6-10(14)13-7-11(15)16-8-9-4-2-1-3-5-9;1-6-2-4-7(5-3-6)11(8,9)10/h1-5H,6-8,12H2,(H,13,14);2-5H,1H3,(H,8,9,10)

Upstream product

• 556-50-3 glycylglycine 
• 104-15-4 toluene-4-sulfonic acid 
• 100-51-6 benzyl alcohol 

Downstream Products

• 84983-78-8 N-tert-butyloxycarbonyl-glutamyl-glycylglycine benzyl ester 
• 31953-81-8 Boc-PGG-OCH₂Ph 
• 112613-27-1 N-Benzyloxycarbonyl-(RS)-(5-benzyloxy-2-pyridyl)glycyl-glycylglycinbenzylester 
• 71145-35-2 succinyl-Gly-Gly-OBzl 
• 17293-97-9 Trt-Gly-Gly-Gly-Gly-OBn 
• 173723-57-4 Trt-Gly-Phe-Gly-Gly-OBn 
• 2387-23-7 1,3-Dicyclohexylurea 
• 255851-82-2 {2-[6-tert-butoxycarbonylamino-2-(9H-fluoren-9-ylmethoxycarbonylamino)-hexanoylamino]-acetylamino}-acetic acid benzyl ester 
• 446235-34-3 N-[(benzyloxycarbonylmethyl-carbamoyl)-methyl]-oxalamic acid tert-butyl ester 
• 804483-32-7 [2-(3-{[(benzyloxycarbonylmethyl-carbamoyl)-methyl]-carbamoyl}-propionylamino)-acetylamino]-acetic acid tert-butyl ester 
• 562076-70-4 [2-(2-dioctadecylcarbamoylmethoxy-acetylamino)-acetylamino]-acetic acid benzyl ester 
• 874305-98-3 C₁₈H₂₃⁽²⁾H₂N₃O₆ 
• 874305-95-0 [2-(2-dipropylcarbamoylmethoxy-acetylamino)-acetylamino]-acetic acid benzyl ester 
• 684641-83-6 PGG-OCH₂Ph hydrochloride 

Relevant articles and documents

Fluorescent, synthetic amphiphilic heptapeptide anion transporters: Evidence for self-assembly and membrane localization in liposomes

Synthetic anion transporters (SATs) of the general type (n-C 18H37)2N-COCH2OCH 2CO-(Gly)3-Pro-(Gly)3-O-n-C7H 15, 1, are amphiphilic peptides that form anion

Cation dependence of chloride ion complexation by open-chained receptor molecules in chloroform solution

Seventeen peptides, most having the sequence GGGPGGG, but differing in the C- and N-terminal ends, have been studied as anion-complexing agents. These relatively simple, open-chained peptide systems interact with both chloride and the associated cation. Changes in the N- and C-terminal side chains appear to make little difference in the efficacy of binding. NMR studies suggest that the primary interactions involve amide NH contacts with the chloride anion, and CD spectral analyses suggest a concomitant conformational change upon binding. Changes in binding constants, which are expected in different solvents, also suggest selective solvent interactions with the unbound host that helps to preorganize the open-chained peptide system. Significant differences are apparent in complexation strengths when the heptapeptide chain is shortened or lengthened or when the relative position of proline within the heptapeptide is varied.

Synthesis, radiolabelling and biological evaluation of terminal oxamide derivatives of mercaptoacetyltriglycine

99mTc-MAG3 is widely used in clinical nuclear medicine as a potential replacement of 131I-OIH for renal function studies. The terminal carbonylglycine in the MAG3 backbone is assumed to be essential for maintain